Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

gandolf63 Jul. 3 at 7:56 PM

$AUTL one of the questions from the last conference call was…..“Then the second one on multiple sclerosis... I know it's early, but just wanted to see if you guys could provide any color on your commercialization plan there. Are you planning to go at this yourself, or would you look to a partner or in-license for this indication? Thank you. Atlassian ROVO” the ceo’s response was ”Christian Itin CEO “From that perspective, it does make sense to consider, certainly a commercial approach where you would operate in collaboration with a partner, and that is certainly one of the areas that we are exploring.

2 · Reply

Biotechs5454 Jul. 2 at 6:31 PM

$AUTL My investment thesis for AUTL. Have nothing more to offer.

0 · Reply

nnnuuu Jul. 2 at 8:52 AM

$AUTL i thought with the recent positive earnings this would be up more by now. took my small (really tiny, was speculative position) profit but considering getting back in here. are there any recent analyst ratings or upgrades to note?

0 · Reply

gandolf63 Jul. 2 at 12:00 AM

$AUTL BioNTech has not changed the amount of shares it holds in Autolus Therapeutics since its initial investment. i would love to see them buy out the company this year for $10

3 · Reply

Michael_garic Jul. 1 at 2:04 PM

$AUTL This week my FATE stock is doing much better than AUTL. AUTL is still by far my biggest holding and I believe we are in for some upside surprises before the summer is over. I think having an activist institutional holder like MAK will eventually drive the stock price. Seems like now MAK is OK with just continuing to accumulate.

2 · Reply

gandolf63 Jul. 1 at 1:37 PM

$AUTL Over the last 12 months, institutions have bought more stock of Autolus Therapeutics (NASDAQ: AUTL) than they have sold, bringing overall institutional ownership to approximately 72.8%.Institutional buying and selling metrics for the period show a net positive inflow:Institutional Buyers: 41 funds and institutions opened or added to their positions.Institutional Sellers: 25 funds completely sold out or reduced their holdings.Inflows vs. Outflows: Institutional inflows totaled $60.20 million compared to outflows of $35.27 million.

1 · Reply

Biotechs5454 Jun. 30 at 3:44 PM

$AUTL what does MAK see that everyone else doesn’t? These guys aren’t always right, for certain, but for them to pile in as much as they have always makes me pause before bailing.

2 · Reply

XX1XX Jun. 30 at 3:12 PM

$AUTL XBI is ripping and AUTL is stuck in mud, when XBI pulls back AUTL will drop like a stone.

1 · Reply

Biotechs5454 Jun. 30 at 3:12 PM

$AUTL Here’s the interesting thing. Being objective, I actually think Itin has done what he has set out to do. As much as I want to blame him, I can’t really. The problem is that the science, the basic premise/purpose of the company, is of limited interest to investors. The safety profile is undisputed. I hope I’m wrong and maybe the readouts later this year will inject some excitement into their pipeline and technology.

2 · Reply

Biotechs5454 Jun. 30 at 3:07 PM

$AUTL I pondered swapping AUTL for FATE when fate dropped to 1.8x a couple days ago. Good idea, poor execution lol.

3 · Reply

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2026, 9:00 AM EDT - 4 days ago

Autolus Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 25, 2026, 7:00 AM EDT - 9 days ago

Autolus Therapeutics to Participate in Upcoming Investor Conference

Jun 12, 2026, 4:00 AM EDT - 22 days ago

Autolus Therapeutics Receives Prix Galien UK Award

Jun 3, 2026, 10:30 AM EDT - 4 weeks ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 2:20 PM EDT - 4 weeks ago

Autolus Therapeutics Transcript: 46th Annual William Blair Growth Stock Conference

May 27, 2026, 7:00 AM EDT - 5 weeks ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

May 21, 2026, 5:10 PM EDT - 6 weeks ago

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

May 21, 2026, 7:00 AM EDT - 6 weeks ago

Autolus Therapeutics Slides: Corporate presentation

2026-05-14T18:12:04.000Z - 7 weeks ago

Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright

2026-05-14T12:45:01.000Z - 7 weeks ago

Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)

2026-05-14T12:43:51.000Z - 7 weeks ago

Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Autolus Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Autolus Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Autolus Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 7 weeks ago

Autolus Therapeutics Slides: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 5, 2026, 7:00 AM EDT - 2 months ago

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

2026-04-29T22:04:39.000Z - 2 months ago

Autolus Therapeutics to reduce workforce by approximately 13%

Apr 29, 2026, 4:05 PM EDT - 2 months ago

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Apr 13, 2026, 10:15 AM EDT - 2 months ago

Autolus Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Autolus Therapeutics Registration statement: Registration filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Autolus Therapeutics Registration statement: Registration filing

Apr 13, 2026, 7:00 AM EDT - 2 months ago

Autolus Therapeutics Slides: Corporate presentation

2026-04-13T10:06:36.000Z - 2 months ago

Autolus Therapeutics files to sell 54.58M American Depositary Shares for holders

2026-04-13T10:06:09.000Z - 2 months ago

Autolus Therapeutics files $150M mixed securities shelf

Apr 8, 2026, 1:00 PM EDT - 3 months ago

Autolus Therapeutics Transcript: Status update

Apr 8, 2026, 1:00 PM EDT - 3 months ago

Autolus Therapeutics Slides: Status update

2026-03-31T11:07:21.000Z - 3 months ago

Autolus Therapeutics price target lowered to $10 from $12 at Mizuho

Mar 27, 2026, 8:30 AM EDT - 3 months ago

Autolus Therapeutics Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 3 months ago

Autolus Therapeutics Annual report: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 3 months ago

Autolus Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 3 months ago

Autolus Therapeutics Slides: Q4 2025

2026-03-27T11:36:34.000Z - 3 months ago

Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)

Mar 27, 2026, 7:00 AM EDT - 3 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 16, 2026, 4:10 PM EDT - 3 months ago

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Mar 3, 2026, 11:10 AM EST - 4 months ago

Autolus Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-17T11:11:16.000Z - 4 months ago

Autolus Therapeutics initiated with a Buy at H.C. Wainwright

2026-02-13T11:43:09.000Z - 5 months ago

Autolus Therapeutics price target lowered to $8 from $11 at H.C. Wainwright

2026-01-13T14:02:20.000Z - 6 months ago

Autolus Therapeutics price target lowered to $8 from $10 at Truist

2026-01-12T16:55:27.000Z - 6 months ago

Autolus Therapeutics price target lowered to $10 from $11 at Needham

2026-01-12T12:11:24.000Z - 6 months ago

Autolus Therapeutics sees Q4 AUCATZYL revenue of $24M

2026-01-12T12:11:07.000Z - 6 months ago

Autolus Therapeutics sees FY26 AUCATZYL revenue $120M-$135M

2026-01-12T12:10:09.000Z - 6 months ago

Autolus Therapeutics sees cash runway into 4Q27

Jan 12, 2026, 7:00 AM EST - 6 months ago

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Jan 6, 2026, 9:00 AM EST - 6 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Jan 6, 2026, 9:00 AM EST - 6 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

$Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025$

Dec 8, 2025, 4:05 PM EST - 7 months ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 8:35 AM EST - 7 months ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 1, 2025, 7:00 AM EST - 7 months ago

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

$NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹$

Nov 25, 2025, 4:00 AM EST - 7 months ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Nov 18, 2025, 7:30 AM EST - 8 months ago

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 4:05 PM EST - 8 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 8:30 AM EST - 8 months ago

Autolus Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

Autolus Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

Autolus Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

Autolus Therapeutics Slides: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 3, 2025, 9:05 AM EST - 8 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 9 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Sep 16, 2025, 8:05 AM EDT - 10 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Autolus Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Autolus Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Autolus Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Autolus Therapeutics Slides: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 1 year ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 11, 2025, 1:20 PM EDT - 1 year ago

Autolus Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 14, 2025, 9:30 AM EDT - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Autolus Therapeutics Registration statement: Registration Filing

May 8, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 1 year ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Status Update

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Press release: Status Update

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Status Update

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 9, 2025, 9:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 12, 2025, 8:40 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Jan 17, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 8:00 AM EST - 1 year ago

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Slides: Q3 2024

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Transcript: FDA Announcement

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Press release: FDA Announcement

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Slides: FDA Announcement

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Slides: Q2 2024

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Jun 12, 2024, 2:40 PM EDT - 2 years ago

Autolus Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 1, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Status Update

May 31, 2024, 8:00 AM EDT - 2 years ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Quarterly report: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings release: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Slides: Q1 2024

May 17, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Apr 24, 2024, 10:00 AM EDT - 2 years ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 11, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Autolus Therapeutics Annual report: Q4 2023

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Autolus Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Autolus Therapeutics Slides: Q4 2023

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

gandolf63 Jul. 3 at 7:56 PM

2 · Reply

Biotechs5454 Jul. 2 at 6:31 PM

$AUTL My investment thesis for AUTL. Have nothing more to offer.

0 · Reply

nnnuuu Jul. 2 at 8:52 AM

0 · Reply

gandolf63 Jul. 2 at 12:00 AM

$AUTL BioNTech has not changed the amount of shares it holds in Autolus Therapeutics since its initial investment. i would love to see them buy out the company this year for $10

3 · Reply

Michael_garic Jul. 1 at 2:04 PM

2 · Reply

gandolf63 Jul. 1 at 1:37 PM

1 · Reply

Biotechs5454 Jun. 30 at 3:44 PM

$AUTL what does MAK see that everyone else doesn’t? These guys aren’t always right, for certain, but for them to pile in as much as they have always makes me pause before bailing.

2 · Reply

XX1XX Jun. 30 at 3:12 PM

$AUTL XBI is ripping and AUTL is stuck in mud, when XBI pulls back AUTL will drop like a stone.

1 · Reply

Biotechs5454 Jun. 30 at 3:12 PM

2 · Reply

Biotechs5454 Jun. 30 at 3:07 PM

$AUTL I pondered swapping AUTL for FATE when fate dropped to 1.8x a couple days ago. Good idea, poor execution lol.

3 · Reply

Michael_garic Jun. 30 at 2:37 PM

$AUTL Webcast part 3 Question: what advantages does AUTL as a commercial company have over companies still in clinical trials. Answer: Proven track record of results and safety especially with neural toxicity. Approved, commercially available product with a robust, real world data set. Very high manufacturing yield and success rate compared to other CAR T companies at this stage. 80 established centers gives AUTL a strong presence/footprint. Question: MS trial progress Answer: Currently there is no treatment that will penetrate the blood brain barrier. Obe cel has proven, based on Leukemia patients that it can penetrate and work on cells in the brain. Question: Milestones Answer: Q4 update on Lupus, AUTO 8, update on ROCCA real world obe cel experience. Q1 2027 MS update, Q4 2027 Pediatric ALL Mid 2028 end point of Lupus study.

1 · Reply

Michael_garic Jun. 30 at 2:23 PM

$AUTL Webcast part 2 Still working on the European launch. Only launching where it makes economic sense. Question: Moving obe cel to earlier lines of treatment Answer: Drug is currently available for second line of treatment. Two studies are active and one just being started on using obe cel as first line treatment. Data at the end of 2027. If the studies are positive and the NCCN accepts the treatment then the physicians/hospital can get reimbursed but the company cannot promote it as a front line treatment. Question: Pediatric market increase and cost to run study Answer: Will need a few dedicated centers but factory will be minimally impacted. Question: Immunotherapy progress Answer: Data shows improvement in 80% of very seriously impacted patients. Update end of 2026. No current therapy has shown the improvement that the obe cel trial has shown.

0 · Reply

Michael_garic Jun. 30 at 2:01 PM

$AUTL My take from the webcast this morning between Wainwright rep and Christian Itin: Question: What make you confident you can make the projected revenue Answer: Positive feedback on patients via ROCCA consortium tracking 60% of treated patients, including patients that previously were difficult to treat due to the very positive safety profile of the product. Also patients with a low disease burden had very positive outcomes. The positive ROCCA data resulted in a large number of patients being registered putting the company in a very strong trajectory for 2026. Continued increase in prescribing physicians. A straight up line on physicians using the product. 80 centers were expected to be on boarded in 2026 but that number has already been reached. Question: How is the UK market Answer: This is our home market so we have a lot of focus here. Product deemed cost efficient for the NHS. Strong launch in the UK market which is 20% of US market size. Product is accelerating faster in UK.

1 · Reply

Michael_garic Jun. 29 at 12:03 PM

$AUTL Reminder the HC Wainwright investor conference is tomorrow June 30, 2026. If you want to dial in: https://www.autolus.com/investor-relations-media/events/

2 · Reply

Casiel Jun. 26 at 2:36 PM

$AUTL Lumina

0 · Reply

Michael_garic Jun. 26 at 1:56 PM

$AUTL I know some people don't agree, but I think the Fintel short share availability number, even though not a reflection of all short shares available, shows a relative number of short shares available. The fact that this number went from 2M to 7M shares available tells me that MAYBE some shorts are getting out. Might be just hopium on my part but I think the stock will find and settle on a more realistic price reflecting the real value of the business. Have to wait till the next short report mid-July to know for sure but in the meantime it might be worth watching the Fintel number and how it affects price. Again... I am not an expert at this but just trying to use common sense.

0 · Reply

Michael_garic Jun. 25 at 7:23 PM

$AUTL seems to be pinging between the two resistance points $1.60 - $1.71.

0 · Reply

Biotechs5454 Jun. 25 at 3:25 PM

$AUTL Lots of barcoding on AUTL this morning.

0 · Reply

Biotechs5454 Jun. 25 at 3:16 PM

$AUTL This seems like a pretty rational group here. While we all impatiently patiently wait… what other high risk/reward biotechs are you in and what is the thesis?

5 · Reply

Michael_garic Jun. 25 at 12:13 PM

$AUTL https://finance.yahoo.com/healthcare/articles/autolus-therapeutics-participate-upcoming-investor-110000548.html

0 · Reply

Biotechs5454 Jun. 25 at 12:30 AM

$AUTL someone really bought 50k shares of this ticker after hours or likely someone just selling to themselves for whatever reason.

0 · Reply

medinapj Jun. 24 at 2:56 PM

$AUTL No chance of two good days in a row 🤬 with this stock.

0 · Reply

Market Cap	420.53M
Revenue (ttm)	75.39M
Net Income (ttm)	-287.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-381.39%
Debt to Equity Ratio	0.00

Volume	1,442,600
Avg Vol	1,391,114
Day's Range	N/A - N/A
Shares Out	266.16M
Stochastic %K	42%
Beta	2.04
Analysts	Strong Sell
Price Target	$8.48